GlassScriptPhysician profile
Thomas Y Chun
NPI 1407846827
$10,504.14
in general payments reported to CMS, 2019-2025
39 companies · $560 in 2025
The $560 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,470 · 2020: $587 · 2021: $1,154 · 2022: $1,408 · 2023: $2,917 · 2024: $407 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,445 · Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,444.61 |
| Food and Beverage | $1,439.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,191.71 | 2021-2023 | Axonics, Bulkamid |
| Neotract INC. | $2,736.09 | 2019-2020 | |
| Teleflex LLC | $1,220.50 | 2021-2023 | Urolift |
| Astellas Pharma US INC | $540.97 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $374.44 | 2024-2025 | Gemtesa |
| Boston Scientific Corporation | $291.14 | 2019-2025 | Bulkamid, Axonics |
| Medtronic USA, INC. | $221.67 | 2019-2020 | |
| Pfizer INC. | $194.18 | 2019-2021 | |
| Medtronic, INC. | $187.36 | 2021-2025 | Interstim |
| Myovant Sciences INC. | $147.95 | 2021 | |
| Myriad Genetic Laboratories, INC. | $116.28 | 2021-2025 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $114.14 | 2019-2020 | |
| Urogen Pharma, INC. | $113.96 | 2023 | Jelmyto |
| Koelis INC. | $98.86 | 2021 | |
| Bard Access Systems, INC. | $82.14 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.